Diabetes

In individuals with type 2 diabetes with no previous insulin treatment, once-weekly injections of insulin icodec resulted in glucose-lowering efficacy and a safety profile similar to individuals who took once-daily insulin glargine U100.

A higher volume of exercise training may improve glycemic control more in individuals with type 2 diabetes (T2D) compared with individuals who exercise less frequently, according to a stud in Medicine & Science in Sports & Exercise.

The American Journal of Managed Care® recently hosted a Peer Exchange that featured discussion among a panel of expert cardiologists and managed care decision makers regarding how cardiovascular outcome trial results are impacting the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure and how these drugs are shaping heart failure outcomes for patients. Panelists were Nihar R. Desai, MD, MPH, assistant professor of medicine in the cardiovascular medicine section of the Yale School of Medicine and investigator in the Center for Outcomes Research and Evaluation in New Haven, Connecticut; Jaime Murillo, MD, national senior director of cardiology at UnitedHealthcare in Fort Lauderdale, Florida; and Steven Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at the Cleveland Clinic in Cleveland, Ohio. The moderator was Neil B. Minkoff, MD, chief medical officer of Coeus Consulting Group in Sudbury, Massachusetts.

An editor from The American Journal of Managed Care® spoke with Darren K. McGuire, MD, MHSc, to discuss the impact of the results of cardiovascular outcome trials on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure in real-world clinical practice. McGuire is professor of medicine, director of the cardiology clinical trials unit, and director of the Parkland Hospital and Health System outpatient cardiology clinics at the University of Texas Southwestern Medical Center in Dallas.

Peer mentor interventions did not improve long-term hemoglobin A1C levels or yield sustained benefits among veterans with poorly controlled type 2 diabetes (T2D), according to study results published in JAMA Network Open.

Children and adolescents initiating selective serotonin reuptake inhibitors (SSRIs) may be at a small increased risk of developing type 2 diabetes, according to a recent study published in JAMA Psychiatry.

Dulaglutide reduces liver fat content in patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease, when used in combination with standard T2D treatment.

In a cohort study, investigators from Denmark used nationwide register data to analyze the relationship between influenza vaccinations and cardiovascular outcomes among individuals with diabetes.

A Boxed Warning on increased risk of leg and foot amputations has been removed from the label of canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor.

A 16-week trial involving children with type 1 diabetes (T1D) found glucose level was in the target range for a greater percentage of time in individuals who used a closed-loop system compared with those who used a sensor-augmented insulin pump.

In individuals with type 2 diabetes and comorbid obesity, the metabolic benefits of gastric bypass surgery and diet were similar and related to weight loss itself, but it had no clinically important effects independent of weight loss.